Journal of Shandong University (Health Sciences) ›› 2018, Vol. 56 ›› Issue (9): 11-16.doi: 10.6040/j.issn.1671-7554.0.2018.251

Previous Articles     Next Articles

Combinatorial anti-PD-1 and endostatin therapeutic efficacy in Lewis lung cancer mice

JIANG Yunfeng, DONG Xiaopeng, ZHAO Xiaogang   

  1. Department of Thoracic Surgery, the Second Hospital of Shandong University, Jinan 250033, Shandong, China
  • Published:2022-09-27

PDF (PC)

230

Abstract: Objective To explore the antitumor effect of anti-PD-1 combined with angioendostatin on lung cancer in Lewis mice. Methods Lewis lung cancer C57BL/6 mice models were constructed and randomly divided into 4 groups: group A(PBS control), group B(anti-PD-1), group C(endostatin)and group D(anti-PD-1 combined with endostatin). The tumor volume was measured. The content of INFγ in the plasma was detected with ELISA, and the CD31 and VEGF contents were determined with immunohistochemistry. Results Compared with group A, group B and D had significantly inhibited tumor growth(P<0.001); group C had reduced tumor size but there was no statistical difference(P=0.084). Compared with group A, groups D, C and B had significantly elevated INFγ concentration(P<0.001), and group D showed the most obvious increase. Compared with group A, group D had significantly lower positive expression of VEGF(P<0.001). MVD count decreased significantly in group D compared with that in group A(P<0.001), group D compared with group B(P=0.019), and group D compared with group C(P<0.001). Conclusion Anti-PD-1 combined with endostatin can significantly slow down the tumor growth, effectively improve the tumor microenvironment, and play a synergistic antitumor effect.

Key words: Lung cancer, Programmed cell death-1, Endostatin, Tumor microenvironment

CLC Number: 

  • R734.2
[1] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[2] Zeng H, Zheng R, Guo Y, et al. Cancer survival in China, 2003-2005: a population-based study[J]. Int J Cancer, 2015, 136(8): 1921-1930.
[3] Zheng YW, Li RM, Zhang XW, et al. Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome[J]. Cancer Invest, 2013, 31(3): 197-205.
[4] Folkman J. Tumor angiogenesis: therapeutic implications[J]. N Engl J Med, 1971, 285(21): 1182-1186.
[5] O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth[J]. Cell, 1997, 88(2): 277-285.
[6] Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy[J]. Angiogenesis, 2017, 20(2): 185-204.
[7] Liang J, Liu X, Xie Q, et al. Endostatin enhances antitumor effect of tumor antigen-pulsed dendritic cell therapy in mouse xenograft model of lung carcinoma[J]. Chin J Cancer Res, 2016, 28(4): 452-460.
[8] Folkman J, Watson K, Ingber D, et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia[J]. Nature, 1989, 339(6219): 58-61.
[9] Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action[J]. Exp Cell Res, 2006, 312(5): 594-607.
[10] Zhao X, Su Y, You J, et al. Combining antiangiogenic therapy with neoadjuvant chemotherapy increases treatment efficacy in stage IIIA(N2)non-small cell lung cancer without increasing adverse effects[J]. Oncotarget, 2016, 7(38): 62619-62626.
[11] Gampenrieder SP, Westphal T, Greil R. Antiangiogenic therapy in breast cancer[J]. Memo, 2017, 10(4): 194-201.
[12] Yao S, Zhu Y, Chen L. Advances in targeting cell surface signaling molecules for immune modulation[J]. Nat Rev Drug Discov, 2013, 12(2): 130-146.
[13] Siwiec A, Majdan M. The role of the PD-1 protein in pathogenesis of autoimmune diseases, with particular consideration of rheumatoid arthritis and systemic lupus erythematosus[J]. Postepy Hig Med Dosw(Online), 2015, 69: 534-542. doi:10.5604/17322693.1150784.
[14] Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1(MDX-1106)in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates[J]. J Clin Oncol, 2010, 28(19): 3167-3175.
[15] Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med, 2012, 366(26): 2443-2454.
[16] Qian N, Gao L, Dong L, et al. Construction, expression, purification, and characterization of a dual-targeting PD-1/VEGF-A fusion protein(P-V)[J]. Protein Expr Purif, 2015, 109: 1-6. doi:10.1016/j.pep.2015.01.004.
[17] Schmittnaegel M, Rigamonti N, Kadioglu E, et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade[J]. Sci Transl Med, 2017, 12, 9(385). doi:10.1126/scitranslmed.aak9670.
[18] Yasuda S, Sho M, Yamato I, et al. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2(VEGFR2)induces synergistic anti-tumour effect in vivo[J]. Clin Exp Immunol, 2013, 172(3): 500-506.
[19] Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy[J]. Science, 2005,307(5706): 58-62.
[20] Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis[J]. Nat Med, 2013, 19(11): 1423-1437.
[21] Gunaje JJ, Bahrami AJ, Schwartz SM, et al. PDGF-dependent regulation of G protein signaling-5 expression and vascular smooth muscle cell functionality[J]. Am J Physiol Cell Physiol, 2011, 301(2): C478-489.
[22] 何朗, 孙永红, 蒋莉, 等. rh-Endostatin与肿瘤血管正常化时相的关系初探[J]. 中华肿瘤防治杂志, 2016, 23(19): 1291-1296. HE Lang, SUN Yonghong, JIANG Li, et al. Preliminary research of the relationship between rh-Endostatin and micro-vascular normalization course[J]. Chin J Cancer Prevention Treatment, 2016, 23(19): 1291-1296.
[23] Peng Q, Li M, Wang Z, et al. Polarization of tumor-associated macrophage is associated with tumor vascular normalization by endostatin[J]. Thorac Cancer, 2013, 4(3): 295-305.
[24] Ishikawa H, Nakao K, Matsumoto K, et al. Antiangiogenic gene therapy for hepatocellular carcinoma using angiostatin gene[J]. Hepatology, 2003, 37(3): 696-704.
[1] HUANG Peiwen, WANG Xudong. A new drug for non-small cell lung cancer: Telisotuzumab Vedotin, an antibody-drug conjugate targeting c-Met protein [J]. Journal of Shandong University (Health Sciences), 2026, 64(3): 124-130.
[2] WANG Lei, CHANG Xiao, WANG Zimeng, LI Jiaojiao, CUI Shujun, YANG Fei, ZHU Yuexiang. Predictive value of intratumoral and peritumoral DCE-MRI imaging histology for progression-free survival in patients with cervical cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(6): 45-54.
[3] ZHAO Hanqing, ZHOU Xinrui, LI Zijian, TANG Xing. Application of circulating tumor cells combined with serological detection in non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(5): 79-85.
[4] XU Nianxing, WEI Dong, QIAO Junjie, ZHAN Bingyan. Predictive value of CD8+, IL-6, and PaO2 for immunotherapy-triggered radiation recall pneumonitis in unresectable stage ⅢB/C and IV non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(2): 29-35.
[5] Thoracoscopic Committee of Shandong Provincial Endoscopic Surgery Quality Control Center. Shandong Provincial expert consensus on control indexes of VATS/RATS perioperative quality for non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(12): 1-5.
[6] LI Yiyuan, MA Shan, LI Aihua, LONG Fei. EBUS-guided iodine-125 seed implantation for the treatment of central lymph node metastases in lung cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(12): 26-34.
[7] LIU Zhenkun, LYU Jiling, XU Weiwei, MA Litian, ZHANG Caiqing. Value of tNGS testing and conventional culture for BALF in the diagnosis of NSCLC complicated with IPFD [J]. Journal of Shandong University (Health Sciences), 2025, 63(11): 36-45.
[8] SONG Yawen, GUO Liantao, KONG Deguang, SUN Shengrong. VTCN1 causes poor prognosis and endocrine therapy resistance in HR+ breast cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 43-59.
[9] WANG Yanan, LIANG Chuanjie, JIA Mengqi, YUAN Huiqing. Role of protein disulfide isomerase TMX1 in promoting chemotherapy resistance in lung cancer [J]. Journal of Shandong University (Health Sciences), 2023, 61(8): 31-39.
[10] ZHONG Lu, XUE Fuzhong. A Lung cancer risk prediction model based on Bayesian network uncertainty inference [J]. Journal of Shandong University (Health Sciences), 2023, 61(4): 86-94.
[11] CHENG Chuanlong, HAN Chuang, FANG Qidi, LIU Ying, YANG Shuxia, CUI Feng, LIU Jingjing, LI Xiujun. Exploring the environmental influencing factors of lung cancer incidence based on geographically and temporally weighted regression model [J]. Journal of Shandong University (Health Sciences), 2023, 61(4): 95-102.
[12] YANG Yongqing, ZHAO Peng, WANG Yu, MA Wenjing, TIAN Mimi, CHENG Yani, ZU Lu, LIN Xiangtao. Diagnostic value of extracellular volume fraction in 62 cases of different pathological types of lung cancer [J]. Journal of Shandong University (Health Sciences), 2023, 61(2): 88-94.
[13] AI Jiangshan, GAO Huijiang, AI Shiwen, LI Hengyan, SHI Guodong, WEI Yucheng. Diagnostic value of CT radiomics in lung cancer associated with cystic airspaces [J]. Journal of Shandong University (Health Sciences), 2023, 61(12): 70-77.
[14] HAN Jing, JIA Chunling. Effects of periodontal basic therapy on postoperative pneumonia in patients with lung cancer before thoracic surgery [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 113-118.
[15] GAO Zhongxia, ZHANG Ming, FAN Mingde, TAN Chenyang, WANG Mengdi, WANG Chao, FAN Yuefei, DING Shouluan, WANG Chengwei. Efficacy and prognostic factors of gamma knife in treating 81 cases of brain metastases from lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 44-49.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd